Drug Type Bispecific antibody |
Synonyms Anti-Psl/PcrV, BiS4alphaPa, MEDI-3902 |
Target |
Mechanism PcrV inhibitors(Pseudomonas aeruginosa PvrV protein inhibitors), PslG inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pseudomonas Infections | Phase 2 | US | 25 Mar 2016 | |
Pseudomonas Infections | Phase 2 | AT | 25 Mar 2016 | |
Pseudomonas Infections | Phase 2 | BE | 25 Mar 2016 | |
Pseudomonas Infections | Phase 2 | HR | 25 Mar 2016 | |
Pseudomonas Infections | Phase 2 | CZ | 25 Mar 2016 | |
Pseudomonas Infections | Phase 2 | FR | 25 Mar 2016 | |
Pseudomonas Infections | Phase 2 | GR | 25 Mar 2016 | |
Pseudomonas Infections | Phase 2 | HU | 25 Mar 2016 | |
Pseudomonas Infections | Phase 2 | IE | 25 Mar 2016 | |
Pseudomonas Infections | Phase 2 | IL | 25 Mar 2016 |
Phase 2 | 188 | Placebo (Placebo) | izmnpurpui(sxxckbyucz) = uswdgxxawc iyhuruqffb (jsorrlcbvo, hogsfqzuby - hpidmxyiko) View more | - | 23 Dec 2020 | ||
(MEDI3902 500 mg) | izmnpurpui(sxxckbyucz) = ardbshmdxy iyhuruqffb (jsorrlcbvo, mkfrazgjel - dapanhskkb) View more | ||||||
Phase 1 | 56 | Placebo (Placebo) | gnnpvitcnz(xbvstvujiv) = rvtvhlczkz kquzunihle (twcbssdhom, xyqjbkstgk - dmnvbwlpvy) View more | - | 13 Aug 2018 | ||
(MEDI3902 - Dose 1) | gnnpvitcnz(xbvstvujiv) = bngdzfudvc kquzunihle (twcbssdhom, roltisdugg - xfjzaculvj) View more |